A behind-the-scenes look at fastest BLA review in US
This article was originally published in SRA
'Something of a roller coaster', 'a very intense period of interaction', 'a heightened sense of urgency', 'almost daily communication', 'one team working together'.
You may also be interested in...
The FDA emphasized the rigor of its review of the first COVID-19 therapy, which used few expedited pathways on its way to approval after a two-and-a-half-month review. Post-marketing studies will address remaining concerns about dosing and special populations.
Levy, SVP of global development, notes that two years after launching an in-house Center for Design and Analysis, Amgen considers adaptive designs for most new studies and more than half include adaptive elements.
Marinus’s ganaxolone has lost its accelerated assessment status mid-review at the European Medicines Agency while Roche’s glofitamab will be fast-tracked once a filing has been made.